Laboratory Evaluations (Phase III)

• Clinically relevant laboratory abnormalities in hematology and biochemistry values were rare and with similar frequency for tegaserod- and placebo-treated groups

• Liver chemistries (LFTs)

  • ALT > 3-fold normal: tegaserod 0.4% versus placebo 0.2%
  • AST > 3-fold normal: tegaserod 0.1% versus placebo 0.1%
  • No simultaneous elevations in ALT/AST and bilirubin
  • No serious adverse event of hepatitis or elevated LFTs
  • No evidence of tegaserod-induced hepatotoxicity was noted

Previous slide

Next slide

Back to first slide

View graphic version